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Summary
Background: Juvenile myoclonic epilepsy (JME) is not too uncommonly encountered
in Indian neurological practice. A number of reports from different parts of India have
documented the clinical phenomenology and EEG characteristics of this genetically
determined epileptic syndrome. However, no study has yet been reported from the
Eastern part of India and none done so far in patients in a specific ethnic group.
Furthermore therapy response and follow up data are not available in detail in the
Indian studies.
Objective: To study disease expression, EEG characteristics and therapy response of
JME patients in ethnic Bengalees in West Bengal, an Eastern Indian State, in a clinic
based study.
Material and Methods: 200 patients with JME attending the Neurology Department of
the Institute have been followed up for 5 years and different parameters of disease
expression as outlined above have been studied.
Results: Overall clinical disease expression has been found to be similar in this clinic
based study in ethnic Bengalees as compared to other reports from India and else-
where. About 16% of patients showed a relative resistance to Valproate therapy.
Hundred percent of patients in whom therapy withdrawal was attempted, relapsed
within <1—2 years. Amongst female patients (132), 16 developed features of poly-
cystic ovarian syndrome while on Valproate therapy. In over half of them, the
symptoms regressed after successful switch over from Valproate to Clobazam. 12/
132 female patients became pregnant during follow up and while on Valproate;
teratogenic effect was evident in only one such patient.
Conclusions: Phenotypic variations in disease expression including therapy response
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might account for genetic heterogeneity noted in molecular genetic studies. JME
cannot really be called a very ‘benign’ epileptic syndrome; recurrence after therapy
withdrawal almost invariably occurs.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Juvenile myoclonic epilepsy (JME) is a common epi-
lepsy syndrome that is classifiedamong the idiopathic
generalized epilepsies (IGEs). It is a collection of
seizurepatterns that are clinicallydistinct fromthose
in other forms of IGE, with the major characteristic
being adolescence-onset myoclonic seizures.
Although the pathogenesis is unknown, recent
advances, especially in genetics, suggest several
possible mechanisms. JME is both genetically and
clinically heterogeneous; some clinical differences
may indicate differences in pathogenesis in different
groups of patients. The nosology and classification of
IGE syndromes are currently under revision.1,2
The original description by Janz and co-workers3
distils theessential clinical featuresof this syndrome:
‘‘(epilepsy with) impulsive petit mal appears around
puberty and is characterized by seizures with bilat-
eral, single or repetitive arrhythmic, irregular myo-
clonic jerks, predominantly in the arms. Jerks may
cause some patients to fall suddenly. No disturbance
of consciousness is noticeable. Often there are gen-
eralized tonic-clonic seizures (GTCS) and infrequent
absences. The seizures usually occur after awakening
and are often precipitated by sleep deprivation.
Interictal and ictal EEG have rapid generalized, often
irregular spikewaves andpolyspikewaves; there is no
close phase correlation between EEG spikes and
jerks. Frequently the patients are photosensitive.
Response to appropriate drugs is good’’.
In the last few years, over half a dozen studies
have reported on the phenotypic expression of the
JME syndrome in people hailing from the North,
North-Western and Southern parts of India.4—11 To
date, no report has emerged from the Eastern part
of India and certainly not looking at the phenotypic
expression of the disease in a specific ethnic group.
The present study looks at the clinical aspects of
JME in ethnic Bengalees from the Eastern Indian
state of West Bengal in a clinic based study speci-
fically focussing on the natural history of the disease
only enrolling patients where follow up data had
been available for 5 years or more.Material and methods
The present clinic based study has been carried out
through retrospective analysis of case notes of 200patients of ethnic Bengalee origin with JME, attend-
ing the general neurology outpatient department of
the Institute who had completed 5 years or more of
follow up by December, 2004. The cases were first
seen at various times between 1995 and 2000 and
included 162 newly diagnosed cases and 38 diag-
nosed as epilepsy earlier elsewhere. Cases who were
not regularly followed up or had inadequate data or
were inadequately investigated were excluded.
Where needed, patients were contacted to get
details of clinical history and family histories at
the time of compilation of the results (January—
March 2005). As the present study cannot provide
any indication of the incidence of JME amongst our
epilepsy patients, the total number of ‘new’ JME
cases in ethnic Bengalees first seen in 4 years
between 2000 and 2003 (N = 385) vis a vis the total
number of ‘new’ cases of epilepsy in ethnic Benga-
lees seen (N = 3564) during the same period were
noted for analysis.
Although, the present study is essentially a retro-
spective one, a uniform pattern of assessment of
JME patients was evolved much earlier in keeping
with our interest in this particular syndrome.
The inclusion criteria for JME being12: (a) unequi-
vocal clinical (historical) evidence of bilateral myo-
clonic jerks (MJ) beginning in or around early teens
with or without GTCS and/or absence seizures; (b)
no evidence of neurologic or intellectual deficit; (c)
abnormal EEG consisting of generalized spike and/or
multiple spike-wave discharges in untreated or trea-
ted patients (a normal EEG or with background
abnormalities other than well-defined spike-wave
discharges was acceptable only if the above-men-
tioned clinical criteria were strictly justified); and
(d) normal computed tomography (CT)/magnetic
resonance imaging (MRI) scan (occasional minor
abnormalities that could not have been the cause
of the seizures after the relevant investigations
were acceptable). Patients with evidence of neuro-
logic or intellectual deficit or an abnormal CT/MRI of
the brain that could explain the seizure types, and
those with evidence of MJ and/or GTCS secondary to
alcohol withdrawal, substance abuse, brain
hypoxia, metabolic disease, meningo-encephalitis,
degenerative disease, etc. were excluded.11
After initial evaluation, all patients who satisfied
all the criteria for diagnosis of JME, the case notes
were studied, recording the type and frequency of
seizures, precipitating factors for seizures, EEG
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Table 1 Demography (N = 200)
Age of onset (years)
MJ 15.6  2.6
GTCS 15.4  3.2
Absence 12.8  1.2
M = 68; F = 132; M:F = 1:1.94.data, antiepileptic drug (AED) treatment details and
family history. Some patients were recalled for
further evaluation where initial assessment details
seemed inadequate.
At least one conventional scalp EEG following
sleep deprivation with hyperventilation and inter-
mittent photic stimulation (IPS) was recorded (with-
out modification of their current antiepileptic
treatment, if any) on all the probands on presenta-
tion. The IPS was performed using a photic stimu-
lator with stimulator lamp at a distance of 30 cm
from the nasion. The IPS frequencies tested were 5,
10, 15, 20, 25, and 30 Hz in an ascending order with
eyes closed for all the frequencies. The same person
with the knowledge of the patient’s diagnosis
reported all the EEGs that were classified as ‘abnor-
mal’ only when definite bilaterally symmetrical,
generalized spike-wave or polyspike and slow-wave
discharges (including photo-convulsive response
(PCR)) were seen. PCR on the EEG was defined as
occurrence of generalized spike, spike-wave or
polyspike and wave discharges frequently locked
with the stimulus, consistently elicited by IPS and
on occasions outlasting the IPS. CT/MRI of the brain
was performed in all patients and all were normal or
revealed unrelated findings.
Details of family history were elicited specially
is relation to first and second degree relatives
and pedigree charts were drawn. When possible,
affected family members were personally examined
to elicit the type of epileptic seizure and make a
syndromic diagnosis in some (not all) through usual
investigations (EEG, CT).
The treatment schedule followed had been for-
mulated earlier. All patients without any AED treat-
ment (n = 162) were started on Sodium Valproate
15 mg/kg BW and the dosage was gradually
increased till adequate seizure control was achieved
or any significant side effects developed. Patients
already on Sodium Valproate (n = 8) were allowed to
continue on same treatment with dosage adjust-
ment made as and when required. Patients on other
AED (phenytoin, carbamazepine) with inadequate
control of seizures (n = 6) were changed to Sodium
Valproate gradually. However those with adequate
seizure control but on other AED (n = 24) were
allowed to continue the same treatment and result
assessed clinically and electroencephalographically
at 1 year. All female patients received routine Folic
Acid supplements.
Three monthly follow ups were made in all cases
and the results assessed clinically and electroence-
phalographically at 1 year, 2 years and 3 years. At 1
year, in those with inadequate control on Valproate
monotherapy, either dosage was increased to upto
40 mg/kg BW or a second line AED, e.g. Clobazam orLamotrigineadded. Inpatientswithadequatecontrol
onotherAED, thosewithabnormal EEGat 1 yearwere
changed over to Valproate monotherapy gradually.
At 3 years follow up, those with seizure freedom
for 3 years and normal interictal EEG record (with
provocative measure outlined above) on two suc-
cessive occasions at 6 weeks intervals were given
the choice of AED withdrawal. In those who con-
sented, AED withdrawal was attempted slowly, at a
rate approximately 5 mg/kg BW every 6 weeks and
the outcomes noted. Those who relapsed were put
back on their original drug regime.
During the course of Valproate therapy, in female
subjects, menstrual abnormalities were noted in
approximately 30% of subjects. Inadequacy of fund-
ings, prevented detailed endocrinological and ultra-
sound examination of all these subjects. Only those
developing phenotypic Polycystic Ovarian Disease
(PCOD) at 2 years follow up were fully investigated
with help from gynaecological colleagues. In such
cases (n = 16), attempt was made to change the
therapy from Valproate monotherapy to Clobazam
monotherapy and the outcome recorded.
During the course of therapy and follow up,
amongst female patients with JME on Valproate
monotherapy, 12 patients became pregnant. The
pregnancy outcome of these patients will be men-
tioned.Results
Between 2000 and 2003, 3564 ‘new’ patients with
epilepsy with age of onset above 5 years were
encountered. JME constituted 385 cases (M:F =
1:1.79) giving an incidence of 11% in our hospital
based sample of ethnic Bengalees.
The present report however deals with only 200
patients recruited between 1995 and 2000 where
detailed follow up data were available for 5 years or
more (range 5—9 years; mean 6.8 years). There were
68 males and 132 females with a M:F ratio of 1:1.94.
Clinical phenomenology
This is summarized in Tables 1—3. Age at onset for
MJ and GTCS had been similar but absence seizures
when present, occurred a little earlier. MJ occurred
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Table 2 Seizure types (N = 200)
Seizure types
MJ 200 (100%)
GTCS 189 (94.5%)
Absence 13 (6.5%)
Subclassification
MJ + GTCS 184 (92%)
MJ + absence 8 (4%)
MJ + absence + GTCS 5 (2.5%)
MJ alone 3 (1.5%)
Table 3 Seizure precipitating factors (N = 200)
Awakening 115 (57.5%)
Sleep deprivation 138 (69%)
Sudden sound 9 (4.5%)
TV watching 7 (3.5%)
Menstruation 11 (7.5%) *
Examination stress 5 (2.5%)
* Of female patients.
Table 5 Interictal EEG at follow up (N = 200)
A. EEG at 1 year
Normal 144 (72%) All on Valproate monotherapy
Abnormal 56 (28%) On Valproate alone–—22a
On Valproate + Clbz/LTG–—10
Other drugs–—24 (12%)
B. EEG at 2 years
Normal All on Valproate monotherapy
Abnormal On Valproate + Clbz/LTG
Clbz–—Clobazam; LTG–—Lamotrigine.
a Valproate dosage increased upto 40 mg/kg BW.in all cases studied but GTCS occurred in 94.5% case
and absences in only 6.5% cases. Subclassification of
seizure types revealed, combination of MJ and GTCS
in 92% cases while only 8% had combination of MJ
and absence seizures. Still fewer patients had com-
bination of all three seizure types or only MJ and
none in the present series presented only with
absence.
Awakening and sleep deprivation appeared to be
the commonest precipitating factors for either MJ or
GTCS. Some relationship to menstrual cycle could
be established in few patients (7.5%) and examina-
tion related stress in 2.5% cases only. Although TV
watching precipitated attacks in aminority (3.5%) of
patients, none had attacks while working on com-
puters.
EEG characteristics
Generalized symmetrical bursts of polyspikes and
spike waves dominated the interictal records ofTable 4 Interictal EEG at presentation (N = 200)
Normal EEG 36 (18%) (15 patients
on treatment)
Abnormal EEG 164 (82%) (37 patients
on treatment)
Generalized polyspikes/
spike waves
102 (51%)
Generalized single spikes/
sharp waves
28 (14%)
Generalized high
amplitude slow waves
30 (15%)
Photo-convulsive response 4 (2%)most patients at initial evaluation. Fifteen percent
showed generalized bursts of high amplitude
(>100 mV) delta waves. Only a minority (2%) showed
definite photo-convulsive response. None showed
any focal features (Table 4). EEG features during
follow up at 1 year and 2 years are given in Table 5.
AED regime
The principles of drug therapy in the cases studied
have already been mentioned previously. The drug
regime followed by the 200 patients at 1-year follow
up is detailed in Table 6. Most had been receiving
Valproate monotherapy. Twelve percent of patients
were still seizure free on other AED like phenytoin
and carbamazepine. As depicted in Table 5,
although remaining seizure free, in none the inter-
ictal EEG reverted to normal at 1 year. All these
patients were subsequently changed over to Valpro-
ate monotherapy with improvement in EEG out-
come.
The therapy results as evaluated at 3 years follow
up are shown in Table 7. Seventy-five percent
patients remained totally seizure free on Valproate
monotherapy alone in most and Clobazam mono-
therapy in a few (see below). However 6% of
patients appeared to be poor responders with not
too infrequent myoclonic jerks on awakening and
even GTCS. Most of these patients had multiple
seizure types at initial evaluation and were main-
tained on a high dose (upto 40 mg/kg BW) of Valpro-
ate with or without either Clobazam or Lamotrigine
as add on.Table 6 AED regime (at 1-year follow up) (N = 200)
Valproate alone 152 (76%)
Valproate + Clbz 20 (10%)
Valproate + LTG 4 (2%)
Others (PHT, CBZ)a 24 (12%)
a None of these cases had a normal EEG at 1 year; all cases
were gradually changed over to Valproate monotherapy with
normalization of EEG at 2 years follow up (Table 5).
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Table 7 Therapy results (at 3 years follow up) (N = 200)
Total seizure freedom 152 (76%)–—Valproate monotherapy + Clbz monotherapy
>90% seizure freedom 16 (8%)–—Valproate monotherapy + Clbz monotherapy
Fair response (50—90% control; only MJ continuing) 20 (10%)–—Valproate monotherapy; Valproate + Clbz add on
Poor response (<50% response) 12 (6%)–—Valproate monotherapy (upto 40 mg/kg BW);
Valproate + Clbz/LTG add on
Table 9 PCOD features at 2 years follow up (N = 16/
132)
1. ObesityThe causes of less than desirable seizure control
in 48 out of 200 patients (i.e. 24%) were looked into
by careful reviewing of their medical records. In the
group of 16 patients (8%) with >90% seizure free-
dom, only very occasional MJ occurred almost
always precipitated by sleep deprivation. The group
(n = 20, i.e. 10%) with ‘Fair Response’ (50—90%
control) was attributed to some reduction in dosage
needed for gastric intolerance (n = 3) and rising
levels of liver enzymes (n = 5) and occasional non-
compliance in some (n = 2). However in 10 patients,
no clear explanation was apparent. Similarly in the
‘Poor Responder’ group of 12 patients (6%), 4
patients declined to have any add ons to Valproate
(due to cost factor), but in the remaining 8 patients
control had been much less than optimal even with
add ons and no cause was apparent. Thus, in out of
48 patients with less than total seizure control at 3
years follow up, the exact reason for suboptimal
therapy response was not apparent in 18 (18/48, i.e.
37.5%) of subjects. This undoubtedly points towards
the phenomenon of clinical heterogeneity (pharma-
cogenetic) amongst JME patients even hailing from
the same ethnic background. This will be commen-
ted upon later in the article as well.
Results of therapy withdrawal after 3
years seizure freedom
Out of over 150 patients who were totally seizure
free for 3 years or more with at least two normal
interictal EEG (done 6 weeks apart with provocative
techniques outlined earlier), only 130 patients (or
their parents) consented to gradual reduction in
drug dosage with a view to total withdrawal over
a 6 months period. The results as assessed at 5 years
follow up are shown in Table 8.
As is noted, unfortunately, in 100% patients,
seizures recurred; nearly 75% recurrences occurredTable 8 Results of therapy withdrawal (at 3 years) as
assessed at 5 years follow up (N = 130/200)
MJ recurrence 86 (66%)
GTCS recurrence 44 (34%)
Total failure rate 100%
75% recurrence Within 1 year
25% recurrence After 1 year
90% recurrence relate to Sleep deprivationduring tapering (when dosage fell below 10 mg/kg
BW) or within 1 year of total withdrawal. The rest
recurred, after 1 year of drug withdrawal. MJ
recurred in 66% cases and GTCS recurred in 34%
cases at first. Most had both of them subsequently.
All such patients were put back to their original drug
regime with total or near total seizure control at 5
years follow up.
Pregnancy outcome
During the study period 12 patients experienced
their first pregnancy. All had total seizure freedom
for at least 2 years, with normal EEG and were on
Valproate monotherapy (dosage 1000—1200 mg
daily) and received Folic Acid supplementation.
None experienced any seizure recurrence during
pregnancy or in the post-partum period. All under-
went USG pelvis and serum a-fetoprotein estimation
at 16 weeks to assess any fetal abnormality. All were
delivered by LUCS. Eleven out of 12 patients deliv-
ered full term normal fetuses. Only one patient
delivered a cyanotic child who on echocardiography
and catheter study was diagnosed to have tricuspid
atresia. While waiting for surgery, the baby died on
the 21st day after birth.
JME, Valproate and PCOD
Although menstrual irregularities were observed in
about 30% of subjects on Valproate monotherapy,
these were not investigated in detail. Only 16
patients developed phenotypic features (Table 9)
suggestive of PCOD at 2 years follow up. Attempt
was made to switch over these patients to Clobazam2. Hirsutism
3. Amenorrhoea/oligomenorrhoea
4. Anovulationa
5. Positive pelvic USG
6. "LH level; altered LH:FSH ratioa
7. "Androgen level a
": increased; LH: leutinizing hormone; FSH: follicle stimulat-
ing hormone; androgen: testosterme and/or dihydroepiandos-
terone.
a Assessed by gynaecologist and endocrinologist.
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Table 10 PCOD–—results of therapy switch from
Valproate to Clobazam (N = 16/132)
Seizure recurrence 7 (all put back
on Valproate)
Successful 9
Regular menstruation 9
Regression of USG features 9
Decreased hirsutism and obesity 6monotherapy and the results are shown in Table 10.
Seizures recurred in seven, who were put back on
Valproate. Nine patients were successfully switched
over and remained seizure free (Table 10). All nine
patients had regular menstruation established
within 3 months of switch over and after 1 year
showed regression of PCO features by pelvic ultra-
sound. Reduction of hirsutism and obesity were
noted in six of nine patients.
The reasons for choosing Clobazam had been the
easy availability of the drug in India, lower cost and
absence of any major side effects and lesser need
for close hematological and other biochemical mon-
itoring (as had been our past experience) thereby
further reduction in cost of therapy. Also menstrual
irregularities had never been found by us in the past,
in women on Clobazam monotherapy with other
forms of IGE where Valproate could not be pre-
scribed (mostly due to gastric intolerance) or
needed to be withdrawn (e.g. occurrence of viral
hepatitis, raised liver enzymes, raised serum ammo-
nia, etc.).
Family study
Amongst these 200 patients, only in 32 (16%) cases a
positive family history of idiopathic epileptic sei-
zures in first (20 cases) and second (12 cases) degree
relatives could be elicited. Out of these only 20 first
degree relatives could be personally examined and
investigated. Of these, only 6 conformed to the
diagnosis of JME and the rest 14 were ascribed to
have IGE. In no families a clear Mendelian pattern
could be established and none of the patients’
parents were affected. The onset symptom of all
six cases with JME had always been with morning MJ
on awakening or precipitated by sleep deprivation.
None had absence seizure. GTCS occurred at some
stage in all patients. The onset age of MJ and GTCS
matched those noted for the patient population.
The other 14 patients had only GTCS and never any
MJ or absences. The onset age varied from 18 to 22
years (mean 19.5  1.6), a figure higher than that
reported for GTCS in the patients under study. The
EEG in the six patients with JME showed the typical
features but none showed photo-convulsive
responses. In the IGE group (n = 14), nine had normalinterictal record and in five symmetrical bursts of
spikes or sharp waves were recorded; and none had
polyspikes or spike-wave changes.Discussion
The present study, though clinic based and carried
out amongst a relatively modest number of patients
is the only Indian study carried out amongst people
of a particular ethnic group. The importance of
carrying out phenomenological studies in a particu-
lar ethnic group will be highlighted later in relation
to known genetic abnormalities detected so far in
JME. Secondly, this also is the only Indian study to
give follow up data specially highlighting the issue of
drug withdrawal. Furthermore, the study throws
some light on the controversial issues of relationship
of PCOD to AED therapy and AED teratogenicity.
The overall incidence of JME, at least in hospital
based population, in the present study in ethnic
Bengalees is not much different from figures quoted
from elsewhere in the world.13—18 However, the
incidence, appears to be higher than those reported
from South India, North-Western India9 and in one
North Indian study.10 However, it approaches the
figure quoted by Jain et al.11 from All India Institute
of Medical Sciences (AIIMS) in New Delhi in North
India.
Also, to note is the little higher prevalence of
females with JME, amongst ethnic Bengalees than in
other parts of India.4—11
Diagnostic delay in JME is well known. From India,
Panagariya et al.9 and Mehndiratta and Agarwal10
gave specific figures in years for this delay in their
study patients. Although we were aware of such
diagnostic delays in many (if not most) of our
patients we were unable to arrive at such specific
figures and wonder how the latter workers could
arrive at such specific figures. In absence of a natio-
nalized health care system in India patients very
oftenmove from one doctor to another and from one
hospital to another often for no apparent reason.
The records handed over to most patients generally
bear no mention of any diagnostic label or simply a
diagnosis of epilepsy without any mention of the
seizure or syndromic diagnosis. It is obvious that in
the patients in the study who were on AEDs other
than Valproate at the time of initial evaluation, the
diagnosis of JME was not made. However, other
patients were put on Valproate elsewhere before
they attended our clinic and it was impossible to be
sure whether such therapy was prescribed after
making a specific diagnosis of JME or not.
The clinical phenomenology of seizure types, EEG
abnormalities and precipitating factors are much
140 A. Chakravarty et al.the same as those reported by other centers from
India4—11 and elsewhere.13—18
The present study also confirms the unequivocally
beneficial effect of Valproate in the management of
JME patients. However, a number of patients, trea-
ted elsewhere were on other AED and enjoyed total
seizure freedom. In none of them, the EEG normal-
ized after 1 year and switching the AED regime to
Valproate did reverse the EEG changes to normal at
2 years follow up. It is therefore suggested that all
patients with JME need to be treated with Valpro-
ate, even though they may have clinical improve-
ment on other AEDs. The most frustrating thing,
which came out of the study had been the results of
drug withdrawal. All patients in whom such
attempts were made, had recurrence of seizures
sooner or later. This is a major factor of concern in
management and patients need to be counseled
properly regarding the likely probability of indefi-
nite treatment.19 If recurrence occurs, these
patients need to be treated with adequate dosage
of Valproate (at least 15—20 mg/kg BW) and we do
not subscribe to the view expressed by Panagariya
et al.9 to leave the patients on a smaller dosage of
the drug.
The earlier study by De Toffel and Autret,20 where
treatment with low dose sodium Valproate was
suggested included only 11 patients, followed up
for only 33 months and continuation of myoclonic
jerks was not taken into account. We firmly believe,
that if one needs to treat a patient, treatment
should be adequate and as full proof as possible.
A further point or concern relates to the small
subset of patients who seemed to have a relative
resistance to Valproate. Drug resistance in JME has
been reported earlier by Gelisse et al.21 and this
occurred in 15.5% of their patients (N = 155). They
identified clinical features associated with drug
resistance namely presence of psychiatric problems
and multiple seizure types (except MJ with
absences). In the present study 16% patients had
not had very satisfactory seizure control and of
these 6% had been really poor responders. Out of
these 32 patients none had MJ alone or MJ with
absence. The figure includes 4/5 of the patients
with MJ + absence + GTCS and the rest had
MJ + GTCS (28/184). In all these patients, though
GTCS were near totally controlled, MJ continued to
occur at 5 years follow up at times. A variable
response to therapy within a group of phenotypically
similar patients having a similar ethnic background
needs worth noting and might point to genetic
heterogeneity even within a same ethnic popula-
tion.
It still remains controversial whether AEDs (spe-
cially Valproate) cause PCOD in young women.22Without getting involved into the controversy
whether the drug or the disease is related to devel-
opment of PCOD, in the present study 16/132
female patients had frank features of PCOD.
Whether this matches the incidence of PCOD in
general population or not is a difficult question
but it is interesting to note two observations. Firstly
all 16 patients had Valproate monotherapy and none
in the group treated with other AEDs developed
PCOD. Secondly, in about half of these patients,
the PCOD features regressed when Valproate was
replaced by Clobazam. These observations may lend
indirect support to the view of association of Valpro-
ate therapy with development of PCOD. Isojervi
et al.23 previously suggested such change over with
good results.
Valproate teratogenicity is well known. One
patient out of 12 delivered an abnormal fetus with
a congenital heart disease. It is surprising that this
anomaly was missed prenataly by USG and devel-
oped even when the mother was on Folic Acid. The
problem of JME, Valproate therapy and teratogeni-
city would continue to be a tricky one as most
patients are young females in the reproductive
phase of their lives.
Out of 200 patients studied, only 32 had a family
history of epilepsy in a first or second degree rela-
tive. This figure is almost half of what had been
quoted by Jain et al.11 Out of these, only 20 could
be, personally examined. Only six conformed to the
diagnostic criteria of JME and the rest were ascribed
as cases of IGE. No patients had any clear Mendelian
pattern of inheritance and none had any affected
parent with epilepsy. Also the relatives with IGE had
a different EEG pattern. These findings underscore
the importance of genetic heterogeneity of JME and
the need for carrying out genetic studies in mono-
ethnic population. One contributory factor account-
ing partly for this difference with Jain et al.’s11
study might had been that those workers included
febrile convulsions and single seizures as well in
their overall figures. Also, secondary seizures were
included but none such were encountered in the
present study.
Several features noted in the present study,
including variability of seizure types, rather low
incidence of familial occurrence and identification
of a subpopulation of patients with relative Valpro-
ate resistance, might point towards phenotypic var-
iation in disease expression even within a specific
ethnic population. This would be in keeping with the
genetic heterogeneity of JME as reported in recent
literature.24—30 Furthermore, we feel that JME can-
not really be called a very ‘‘benign’’ syndrome, as
seizure recurrence almost invariably occurs after
therapy withdrawal.
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